Skip to Main Content

In a shocking reversal, Biogen on Tuesday said that it would resurrect an Alzheimer’s drug that the company previously said had failed and will ask the Food and Drug Administration to approve it.

The company said a “new analysis of a larger dataset” showed that the drug, aducanumab, reduced clinical decline in patients with early Alzheimer’s disease on multiple measures of the drug’s effectiveness. That directly contradicts a decision in March to halt studies of the therapy based on the recommendations of an independent monitoring board that was charged with protecting patients in the study.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • I will like more information and how enter in the trial or how to obtain this medication .Its been sell in another country?

  • Amyloid is unquestionably necessary but not sufficient to cause Alzheimer’s disease (“cause” is meant here as the factor for the clinical manifestations to occur, not necessarily disease etiology). I have yet to see the results of dual therapies targeting amyloid and tau simmultaneously. We managed many diseases with more than one drug. Hypertension, diabetes, HIV, tuberculosis. Why not AD?

Comments are closed.